Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.
Register for our free email digests: